<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967459</url>
  </required_header>
  <id_info>
    <org_study_id>NL44804.101.13</org_study_id>
    <nct_id>NCT01967459</nct_id>
  </id_info>
  <brief_title>Effects Vitamin D Suppletion on Postprandial Leukocyte Activation</brief_title>
  <acronym>DOSFEM</acronym>
  <official_title>Effects of High and Low Dose Vitamin D Suppletion on Postprandial Leukocyte Activation, Oxidative Stress and Vascular Function in Healthy Overweight and Obese Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sint Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sint Franciscus Gasthuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of vitamin D will have a beneficial effect on postprandial leukocyte&#xD;
      activation, oxidative stress and arterial stiffness in vitamin D deficient females. High&#xD;
      doses of vitamin D may have a more pronounced effect than low doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Postprandial lipemia, known to be associated with acute leukocyte activation,&#xD;
      impairs endothelial function and promotes atherosclerosis. Deficiency of vitamin D is&#xD;
      associated with increased cardiovascular risk, but the precise mechanism is still unclear. A&#xD;
      recent pilot study performed in our laboratory showed improved postprandial vascular function&#xD;
      by pulse wave analysis and decreased postprandial leukocyte activation after vitamin D&#xD;
      supplementation. Interestingly, the effects on leukocyte activation were solely found in&#xD;
      females.&#xD;
&#xD;
      Hypothesis: The beneficial effects of vitamin D administration on postprandial leukocyte&#xD;
      activation are mediated by suppression of oxidative stress. High doses of vitamin D may have&#xD;
      a more pronounced effect than low doses.&#xD;
&#xD;
      Objective: To estimate the effect sizes of different doses of vitamin D on postprandial&#xD;
      leukocyte activation markers, oxidative stress and arterial stiffness in vitamin D deficient&#xD;
      females.&#xD;
&#xD;
      Study design: Randomized, double blind pilot study. Study population: Premenopausal&#xD;
      overweight and obese female volunteers with proven vitamin D deficiency, ≥ 18 years of age.&#xD;
&#xD;
      Intervention: Two oral fat load tests (OFLTs) will be performed. After the first OFLT,&#xD;
      volunteers will be randomly assigned to receive a single low dose (75 000 IU) or high dose&#xD;
      (300 000 IU) of cholecalciferol drink. One week later the OFLT will be repeated.&#xD;
&#xD;
      Main study parameters/endpoints: Postprandial leukocyte activation, oxidative stress&#xD;
      parameters and arterial augmentation index.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The use of a single dose of 300 000 IU of cholecalciferol has been established&#xD;
      to be a safe and effective way to correct vitamin D deficiency. Volunteers will be&#xD;
      hospitalized on 2 different days (day 1, day 8) for approximately nine hours each day and&#xD;
      receive an oral fat load. Cholecalciferol will be administered once. Volunteers will be&#xD;
      instructed not to take vitamin D supplements during the study up until 3 months after the&#xD;
      study. The volunteers' general practitioner will be informed on their participation. A total&#xD;
      of 222ml (111ml for each postprandial test) of blood will be drawn. Volunteers will be&#xD;
      allowed to drink only water during the tests. There is a theoretical risk of hypercalcemia&#xD;
      but no excessive risk is involved. Volunteers receive 250 euros for full participation.&#xD;
      Furthermore, volunteers will be told and given advice if they turn out to suffer from&#xD;
      hyperlipidemia or any other condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of vitamin D on leukocyte cluster of differentiation antigen 11b expression</measure>
    <time_frame>2, 4, 6 and 8 hours postprandial</time_frame>
    <description>the differential effect of 75 000 IU low dose vs. 300 000 IU high dose vitamin D on postprandial leukocyte activation markers cluster of differentiation antigen 11b</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D on oxidative stress</measure>
    <time_frame>2,4,6 and 8 hours postprandial</time_frame>
    <description>the differential effect of 75 000 IU low dose vs. 300 000 IU high dose vitamin D on oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D on vascular function</measure>
    <time_frame>0,2,6,8 and 8 hours postprandial</time_frame>
    <description>the differential effect of 75 000 IU low dose vs. 300 000 IU high dose vitamin D on vascular function (Pulse Wave Velocity and Augmentation Index)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Oxidative Stress</condition>
  <condition>Leukocyte Activation Disorder</condition>
  <arm_group>
    <arm_group_label>High dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)</description>
    <arm_group_label>High dose vitamin D</arm_group_label>
    <other_name>D-cura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)</description>
    <arm_group_label>Low dose vitamin D</arm_group_label>
    <other_name>D-cura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years or older;&#xD;
&#xD;
          -  Pre-menopausal;&#xD;
&#xD;
          -  BMI ≥25.0 kg/m2;&#xD;
&#xD;
          -  Vitamin D deficiency, defined by a 25-hydroxyvitamin D level of &lt;30ng/ml;&#xD;
&#xD;
          -  Use of oral contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of any kind of medication except oral contraceptives;&#xD;
&#xD;
          -  Smoking;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Participation in a clinical study less than 6 months before inclusion;&#xD;
&#xD;
          -  The use of (multi)vitamin supplements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Castro Cabezas, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sint Franciscus Gasthuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sint Franciscus Gasthuis</investigator_affiliation>
    <investigator_full_name>M.A. de Vries</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

